Myovant has chalked up a second approval for its flagship drug relugolix from the FDA, becoming the first once-daily oral drug in the US to treat heavy menstrual bleeding associated with uterine ...

The changes included may save some women "thousands of dollars across their lifetimes", according to budget documents.

Relugolix plus the two hormonal drugs are also approved in the US as Myfembree for uterine fibroids, where the GnRH antagonist is also sold on its own as Orgovyx for prostate cancer.

Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin ...